Sharpen pricing, prioritize molecular diagnostics and genomics, and guide R&D and investment amid point-of-care and self-testing disruption.Dublin, Oct. 09, 2026 (GLOBE NEWSWIRE) -- "Clinical Medical ...
4don MSN
Motilal Oswal initiates coverage on Molbio Diagnostics stock with buy, sees 21% upside. Here's why
Motilal Oswal initiated coverage on Molbio Diagnostics with a Buy rating and ₹1,800 target, implying 21% upside. The brokerage sees strong growth potential from decentralised molecular diagnostics, ...
2d
Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that ...
Molecular diagnostics are specialized tests doctors use to look at proteins, RNA, and DNA in and on cancer cells. When you have breast cancer, they show your doctors what’s unique about your tumor so ...
First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumerationExpands CNSide contracted payer ...
Title: "High-Throughput Enteric Testing: Advancing Speed, Scale, and Stewardship" Inside Molecular: Conversations Across BD Molecular Diagnostics is a podcast series exploring the BD Molecular ...
(Nasdaq: CNSY) (“Cerenome” or the “Company ”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the ...
Administrative Aspects of Molecular Diagnostics—Oversight, Regulatory Approval Process, Clinical and Operational Workflows, and Payment Models The following represents disclosure information provided ...
New automation platform brings open, AI-assisted automation to molecular microbiology and NGS workflows, with configurations from €50,000 to €90,000 WOIPPY, FRANCE, October 5, 2026 /EINPresswire.com/ ...
Roche Diagnostics has provided two molecular testing instruments to the Institut National de Santé Publique (INSP), which is supporting the DRC's Ministry of Health-led Ebola response. Roche will ...
Denials of clinical laboratory, molecular diagnostic, and genomics claims rose to 11.2% in 2025 from 8.0% the year before, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results